Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was CAD 11.46 million compared to CAD 6.21 million a year ago. Net loss was CAD 0.511 million compared to CAD 1.15 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.06 a year ago.